Statistics from Altmetric.com
Hutchinson-Gilford progeria syndrome (HGPS) is a rare fatal genetic disorder which is characterised by the very early appearance of accelerated ageing in children. It was first described by Hutchinson1 and Gilford.2 Children with HGPS appear healthy at birth, with distinctive clinical features appearing within the first few years of life, including severe growth retardation, atherosclerosis, incomplete sexual maturation, loss of subcutaneous fat, craniofacial abnormalities, alopecia (hair loss), stiffness of joints, and other skeletal abnormalities including coxa valga (giving a “horse-riding” stance), delayed and abnormal dentition, and scleroderma-like areas of skin, with normal mental and emotional development.3
A specific causal mutation for HGPS in the LMNA gene was identified4,5 and down-regulation of isoforms of the protein arising from the LMNA gene were found in HGPS patients.6 The LMNA gene encodes the A-type lamins, lamins A and C, in which several other laminopathies have their causal mutation.7,8 The heterozygous de novo point mutation is located in exon 11 of the LMNA gene, which is transcribed to lamin A while the shorter lamin C is unaffected by the mutation. The GGC>GGT G608G single-base substitution reveals a cryptic splice site and is proposed to result in a truncated transcript encoding a protein that is 50 amino acid shorter. This mutant protein will be referred to as progerin. A less common mutation in the same codon (GGC>AGC), predicted to have similar effects on lamin A splicing, was also identified.4 Western blots reveal progerin and the normal lamin A protein in HGPS patient cells.5
This hypothesised mechanism raises questions about allelic expression and splicing efficiency. De Sandre-Giovannoli et al4 postulated that only the mutated allele may be expressed in HGPS cells. We now examine lamin A transcript levels in HGPS cells, identify their allelic sources and demonstrate that both alleles are capable of comparable levels of transcription. We further show that progerin splicing is incomplete, leading to coding transcripts derived from both alleles that encode normal lamin A.
Skin fibroblasts were obtained from Coriell Cell Repository (NJ, USA). HGPS strains were AG03198 and AG03513B and correspond to classical forms of HGPS (M Eriksson and F Collins, personal communication). Age-matched control strains were GM03348B and GM02037A. Cell culture and RNA preparation were as described.6,9 Using DNA extracted from fibroblasts, lamin exon 11 and half of intron 11 were amplified using forward and reverse primers, with sequences GGCTCCCACTCGAGCAGCTC and GGAAGAGAAGGCAGGCTCTC, respectively. From RNA extracted from fibroblasts, lamin exons 11 and 12 were reverse-transcribed and amplified with forward and reverse primers, with sequences GGCTCCCACTGCAGCAGCTC and CATGATGCTGCAGTTCTGGG, respectively. Duplicates studies were performed in each case. For sequencing purposes individual products were re-amplified using the same primers. Sequencing and fragment analysis was through the Australian Genome Research Facility.
The major causal mutation for Hutchinson-Gilford progeria syndrome (HGPS) is in the LMNA gene where it leads to abnormal splicing of lamin A. Transcription efficiencies at the mutant and wildtype LMNA alleles were equivalent in HGPS.
This demonstrates an absence of trans-effects and the ability of each allele to express independently.
The mutant allele gave two types of transcripts that encoded truncated and normal lamin A.
Abnormally spliced (progerin) transcript constituted the majority (84.5%) of the total steady-state mRNA derived from the mutant allele.
The abnormally spliced (progerin) transcript was a minority being 40% of all lamin A transcripts obtained from both alleles.
DNA sequencing confirms the HGPS mutation
DNA extraction, amplification, and sequencing confirmed these HGPS cell strains contained the genomic mutation5 which was missing from the control strains. RNA was extracted from HGPS and age-matched control fibroblasts and subjected to RT-PCR. Forward and reverse primers were designed to amplify exon 11 and most of the coding region of exon 12, therefore producing fragments of two sizes: one from the full length transcript (294 bp) and another fragment from the progerin transcript (144 bp). These products were obtained from HGPS strains while only the 294 bp fragment was found for the control strains. The 294 and 144 bp fragments of each sample were each cut and purified from agarose gels, separately re-amplified, and then sequenced. Sequence data confirmed the presence of expected lamin transcript fragments and the mutation (fig 1).
Products from the mutant but not normal allele contain a single BstXI site
The presence of the expected lamin fragments in RT-PCR products was further confirmed by fragment analysis. A 5′ 6-Fam primer 1 was substituted for primer in reactions and analysis by size fractionation showed that the products were within 1 bp of their expected length (fig 2). A large amount of the 294 bp product was routinely present in all samples, with a small amount of a 208 bp fragment that was a minor PCR artefact. The 144 bp fragment was routinely obtained with HGPS samples. The amount of fluorescence detected for each fragment corresponds to the relative amount of fragment present and was used to determine the ratios of progerin to full-length transcripts. Progerin transcripts levels were similar (∼40% of total lamin A in each) in strains of HGPS cells while not present in controls. We identified a single BstXI site in LMNA exon 11 that distinguishes the wildtype and mutant forms of the full-length cDNA. Digestion of mutant 294 bp cDNA resulted in two products of lengths 124 and 170 bp. For 5′ 6-Fam-labelled RT-PCR products, only the 124 bp product was labelled and consequently detected. By definition, products with no mutation lacked the BstXI site, allowing the retention of the labelled 294 bp fragment (fig 3). The 124 bp fragment appeared only in digested HGPS samples and represents the correctly spliced transcript from the mutant allele. Relative fluorescence quantification defined the relative amounts of the two alleles (table 1).
Through partial sequencing of the LMNA gene, it was confirmed that one allele in HGPS skin fibroblast lines AG03198 and AG03513B contains the G608G (GGC>GGT) mutation previously observed in HGPS patients.4,5 Age-matched controls GM03348B and GM02037A did not contain a mutant allele. This mutation was hypothesised to activate a cryptic splice site, causing a deletion of 150 bp in lamin A mRNA. This truncated transcript codes for progerin, lamin A with a 50 aa deletion.4,5 The presence of the progerin mRNA transcript was confirmed in HGPS strains by amplification across the region of deletion in mRNA though the use of an RT-PCR system that generated a 294 bp product from wildtype mRNA but a 144 bp fragment from truncated mRNA. Analysis of RT-PCR products showed that fragments of 294 bp were amplified from HGPS and control cells, while a 144 bp fragment was amplified only from HGPS cells. Separation and detection of fluorescently tagged products confirmed the expected fragment sizes and the presence of the progerin transcript in HGPS cells. Sequence data for 294 bp fragments amplified from full-length LMNA mRNA transcripts in HGPS cells revealed both the wildtype and mutant allele contributed to normally spliced product. In contrast, control cells revealed only the wildtype sequence. We conclude that transcripts arising from both alleles were present in HGPS and therefore that transcription occurred at both LMNA alleles.
These findings are important for two reasons. First, they confirm previous data suggesting that the activation of abnormal splicing in the mutant allele is incomplete.4,5 We identified full-length transcripts from the mutant allele which encode a normal form of lamin A because the base change does not alter the glycine encoded at that site. Second, our results demonstrate that the wildtype LMNA allele is additionally expressed in HGPS. This is in contrast to the findings of De Sandre-Giovannoli et al,4 whose use of polymorphisms within the sequence led to the hypothesis that the wildtype allele of the LMNA gene may not be expressed in HGPS cells. We excluded cross-sample contamination through repeated independent and controlled amplifications, consistency of the data, the absence of a mutant peak corresponding to a mutant allele in the control cells, and consistent quantitative profiles. It is possible that the type of cell studied may have contributed to differences in results, although skin fibroblasts, used in the present study, appear to be a better choice for investigations into progeria than the lymphocytes used by De Sandre-Giovannoli and colleagues, because the disease is manifested predominantly in connective tissue. It is also possible that cells from individual HGPS patients may vary in their responses (which may also affect severity of the disease in vivo) but this does not diminish the conclusion that HGPS fibroblasts are capable of comparable levels of transcription where each allele is expressed and the mutant allele undergoes both normal and abnormal splicing.
Quantitative analysis of labelled full-length and progerin products revealed that the progerin transcript constituted 40% of the total lamin A transcripts. These findings were similar in the HGPS strains. In contrast, each control contained undetectable levels of progerin transcript. BstXI digestion enabled a distinction between full-length wildtype transcripts and the correctly spliced transcripts from the mutant allele, which were originally identical in size and differed by a single nucleotide. From these studies, the correctly spliced transcript from the mutant allele contributed 12–14% of the total full-length transcript. Considering that the full-length transcript was 60% of the total, this means that wildtype full-length transcript constituted around 53% of all lamin A transcript while correctly spliced transcript from the mutant allele contributed 7% of the total transcript population. Approximately half of the total lamin A transcripts arose from each allele, and 84.5% of transcript arising from the mutant allele was abnormally spliced (39.5% of the total). Each allele contributed approximately half of the steady-state transcript level (fig 4).
Several as yet uncharacterised factors should be the subject of further study. First, the present study was not able to make a direct comparison between whole transcription levels of lamin A in different cell lines. Second, the relative quantities and stability of translated progerin have not yet been established.
These findings raise the question of how a minor level of transcript and presumably minor amounts of mutant protein can cause the disease phenotype in the presence of regular lamin A. Progerin presumably functions as a dominant negative by interfering with the structure of the nuclear lamina, intranuclear architecture, and macromolecular interactions that collectively would have a major impact on nuclear function.
We thank the Progeria Research Foundation for their support, the families with HGPS who donated skin samples, and the Progeria Research Consortium.
Conflict of interest: none declared.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.